Can biochemical markers serve as surrogates for imaging in knee osteoarthritis?

Arthritis and Rheumatism

Volumn 56, Issue 12, 2007, Pages 4038-4047

  Davis, C R ^a   Karl, J ^b   Granell, R ^a   Kirwan, J R ^a   Fasham, J ^a   Johansen, J ^c   Garnero, P ^d   Sharif, M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMAGING SYSTEM; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; X RAY ANALYSIS;

EID: 37149048078     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23129     Document Type: Article

References (59)

1. Jordan KM, Sawyer S, Coakley P, Smith HE, Cooper C, Arden NK. The use of conventional and complementary treatments for knee osteoarthritis in the community. Rheumatology (Oxford) 2004;43:381-4.
2. Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger TA Jr, Felts WR, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989;16:427-41.
3. Buckland-Wright JC, Macfarlane DG, Lynch JA, Jasani MK, Bradshaw CR. Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation. Ann Rheum Dis 1995; 54:263-8.
4. Duddy J, Kirwan JR, Szebenyi B, Clarke S, Granell R, Volkov S. A comparison of the semiflexed (MTP) view with the standing extended view (SEV) in the radiographic assessment of knee osteoarthritis in a busy routine X-ray department. Rheumatology (Oxford) 2005;44:349-51.
5. Landewe R, van der Heijde D. Presentation and analysis of radiographic data in clinical trials and observational studies. Ann Rheum Dis 2005;64 Suppl 4:iv48-51.
6. Mazzuca SA, Brandt KD, German NC, Buckwalter KA, Lane KA, Katz BP. Development of radiographic changes of osteoarthritis in the "Chingford knee" reflects progression of disease or nonstandardised positioning of the joint rather than incident disease. Ann Rheum Dis 2003;62:1061-5.
7. Garnero P, Mazieres B, Gueguen A, Abbal M, Berdah L, Lequesne M, et al. Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol 2005;32:697-703.
8. Young-Min SA, Cawston TE, Griffiths ID. Markers of joint destruction: principles, problems, and potential. Ann Rheum Dis 2001;60:545-8.
9. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957;16:494-502.
10. Clarke S, Wakeley C, Duddy J, Sharif M, Watt I, Ellingham K, et al. Dual-energy X-ray absorptiometry applied to the assessment of tibial subchondral bone mineral density in osteoarthritis of the knee. Skeletal Radiol 2004;33:588-95.
11. Dieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993;52:557-63.
12. Peterfy CG, Guermazi A, Zaim S, Tirman PF, Miaux Y, White D, et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004;12:177-90.
13. Garnero P, Peterfy C, Zaim S, Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005;52:2822-9.
14. Otterness IG, Swindell AC, Zimmerer RO, Poole AR, Ionescu M, Weiner E. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 2000; 8:180-5.
15. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-24.
16. Sharif M, Kirwan JR, Elson CJ, Granell R, Clarke S. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 2004;50:2479-88.
17. Sharif M, Granell R, Johansen J, Clarke S, Elson C, Kirwan JR. Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee. Rheumatology (Oxford) 2006;45:522-6.
18. Sharif M, George E, Shepstone L, Knudson W, Thonar EJ, Cushnaghan J, et al. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum 1995;38:760-7.
19. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60:619-26.
20. Bruyere O, Collette JH, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, et al. Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol 2003;30:1043-50.
21. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006; 54:3205-11.
22. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999;42:2356-64.
23. Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 2002;10:707-13.
24. Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992;31:583-91.
25. Hedin PJ, Weitoft T, Hedin H, Engstrom-Laurent A, Saxne T. Serum concentrations of hyaluronan and proteoglycan in joint disease: lack of association. J Rheumatol 1991;18:1601-5.
26. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004;50: 2471-8.
27. Garnero P, Conrozier T, Christgau S, Mathieu P, Delmas PD, Vignon E. Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis 2003;62:939-43.
28. Bruyere O, Collette J, Kothari M, Zaim S, White D, Genant H, et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis 2006;65: 1050-4.
29. Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002;46:3178-84.
30. Huebner JL, Hanes MA, Beekman B, TeKoppele JM, Kraus VB. A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis. Osteoarthritis Cartilage 2002;10:758-67.
31. Hunter DJ, Hart D, Snieder H, Bettica P, Swaminathan R, Spector TD. Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. Rheumatology (Oxford) 2003;42:1311-6.
32. Engstrom-Laurent A, Hallgren R. Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis 1985;44:83-8.
33. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
34. Gineyts E, Mo JA, Ko A, Henriksen DB, Curtis SP, Gertz BJ, et al. Effects of Ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 2004;63:857-61.
35. Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 2006;54: 2496-504.
36. Elliott AL, Kraus VB, Luta G, Stabler T, Renner JB, Woodard J, et al. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 2005;52: 105-11.
37. Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Heinegard D, et al. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 1995;34:306-10.
38. Wolfe F. The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol 1997;24:1486-8.
39. Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723-7.
40. Tyler JA. Chondrocyte-mediated depletion of articular cartilage proteoglycans in vitro. Biochem J 1985;225:493-507.
41. Manicourt DH, Triki R, Fukuda K, Devogelaer JP, Nagant de Deuxchaisnes C, Thonar EJ. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis: relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993;36:490-9.
42. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004;46:333-40.
43. Williams JM, Downey C, Thonar EJ. Increase in levels of serum keratan sulfate following cartilage proteoglycan degradation in the rabbit knee joint. Arthritis Rheum 1988;31:557-60.
44. Thonar EJ, Lenz ME, Klintworth GK, Caterson B, Pachman LM, Glickman P, et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum 1985;28:1367-76.
45. Moller HJ, Larsen FS, Ingemann-Hansen T, Poulsen JH. ELISA for the core protein of the cartilage large aggregating proteoglycan, aggrecan: comparison with the concentrations of immunogenic keratan sulphate in synovial fluid, serum and urine. Clin Chim Acta 1994;225:43-55.
46. Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999;42:534-44.
47. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992;35:35-42.
48. Alvarez L, Peris P, Pons F, Guanabens N, Herranz R, Monegal A, et al. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Arthritis Rheum 1997;40:461-8.
49. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al. Serum CrossLaps One Step ELISA: first application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998;44:2281-9.
50. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984;1:1091-3.
51. Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991;6:639-44.
52. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
53. Engstrom-Laurent A, Hallgren R. Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis 1985;44:83-8.
54. Sharif M, Salisbury C, Taylor DJ, Kirwan JR. Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis. Arthritis Rheum 1998;41:1203-9.
55. Garnero P, Delmas P. Evaluation of a fully automated assay for serum procollagen type 1 N-propeptide in osteoporosis. J Bone Miner Res 2002;17 Suppl 1:S316.
56. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998;334:489-503.
57. Rygg M, Uhlar CM, Thorn C, Jensen LE, Gaughan DJ, Varley AW, et al. In vitro evaluation of an enhanced human serum amyloid A (SAA2) promoter-regulated soluble TNF receptor fusion protein for anti-inflammatory gene therapy. Scand J Immunol 2001;53:588-95.
58. Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C, Garnero P. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis - association with disease progression. Rheumatology (Oxford) 2007;46:938-43.
59. Rousseau JC, Zhu Y, Miossec P, Vignon E, Sandell LJ, Garnero P, et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004; 12:440-7.